Novel approaches in myeloma therapy

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Multiple myeloma treatment is evolving.
• High-dose melphalan (200 mg/m2) followed by autologous peripheral blood stem cell transplantation (aPBSCT) is a recognized regimen.
• Its efficacy in specific patient populations warrants further investigation.

Purpose of the Study:

• To evaluate the safety and efficacy of high-dose melphalan and aPBSCT for multiple myeloma.
• To identify factors associated with adverse outcomes, specifically cytogenetic myelodysplasia.
• To explore strategies for improving sustained complete remission and overall treatment outcomes.

Main Methods:

• Retrospective analysis of patients with multiple myeloma treated with high-dose melphalan and aPBSCT.
• Assessment of treatment efficacy in older patients (>65 years) and those with renal failure.
• Identification of risk factors for cytogenetic myelodysplasia, including age, prior therapy duration, and CD34 mobilization potential.

Main Results:

• High-dose melphalan and aPBSCT is a safe and effective treatment for multiple myeloma.
• This regimen demonstrates comparable efficacy to standard therapy in older patients and those with renal failure.
• Advanced age (>50 years), prolonged prior standard therapy (>12 months), and low CD34 mobilization (<20 x 10(6)/kg) are linked to increased cytogenetic myelodysplasia.

Conclusions:

• High-dose melphalan with aPBSCT is a viable treatment option for multiple myeloma across diverse patient groups.
• Risk stratification is crucial for identifying patients who may benefit from closer monitoring for myelodysplasia.
• Future myeloma treatment should integrate optimized induction regimens with consolidation/maintenance strategies and novel adjunctive therapies to improve long-term outcomes.